A study of HNC364 injectable suspension in patients with Parkinson's disease

Guangzhou Henovcom Bioscience Co. Ltd is starting a new clinical trial of A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable Suspension.

This is a non-randomized, dose-escalation first-in-human study to evaluate the safety, tolerability, PK, and PD of HNC364 following intramuscular administration of single ascending doses.

The clinical trial started in August 22, 2022 and will continue throughout April 5, 2023.

Number of Participants With Treatment Emergent Adverse Events will be primary outcome measure. This safety outcome lists the number of subjects experiencing adverse events (AEs), whether not related, possibly or unlikely related to the study treatment.

For more details: https://ichgcp.net/clinical-trials-registry/NCT05523570.